Detalhe da pesquisa
1.
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
J Clin Pharmacol
; 49(6): 650-60, 2009 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-19451403
2.
A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.
Clin Cancer Res
; 13(23): 7101-6, 2007 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-18056189
3.
Cyclooxygenase-2 and angiogenesis in prostate cancer.
Cancer Biol Ther
; 4(8): 813-4, 2005 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-16123581
4.
Immunomodulation of multiple myeloma.
Cancer Biol Ther
; 3(11): 1060-1, 2004 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-15640623
5.
Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography.
J Chromatogr B Analyt Technol Biomed Life Sci
; 805(1): 135-40, 2004 Jun 05.
Artigo
Inglês
| MEDLINE | ID: mdl-15113549
6.
Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci
; 811(2): 135-41, 2004 Nov 25.
Artigo
Inglês
| MEDLINE | ID: mdl-15522712
7.
Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia.
Leuk Lymphoma
; 52(12): 2284-92, 2011 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-21745173
8.
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
J Clin Oncol
; 28(17): 2839-46, 2010 Jun 10.
Artigo
Inglês
| MEDLINE | ID: mdl-20458040
9.
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.
Clin Cancer Res
; 16(4): 1256-63, 2010 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-20145186
10.
A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.
Clin Prostate Cancer
; 2(4): 241-3, 2004 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-15072608